InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.105 0.015 (12.50%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$13 Argenica Awarded Federal Government Funding 20 Jun 2025 9:54AM $0.720 $0.105 fallen by 85.42%
$13 Argenica to Progress Clinical Development in TBI 18 Jun 2025 8:49AM $0.705 $0.105 fallen by 85.11%
$13 Update on Investigational New Drug Application 10 Jun 2025 8:43AM $0.785 $0.105 fallen by 86.62%
$13 Change of Director's Interest Notice 3 Jun 2025 5:49PM $0.770 $0.105 fallen by 86.36%
$13 Notification of cessation of securities - AGN 3 Jun 2025 5:46PM $0.770 $0.105 fallen by 86.36%
$13 Notification regarding unquoted securities - AGN 3 Jun 2025 5:46PM $0.770 $0.105 fallen by 86.36%
$13 Investor Webinar 23 May 2025 8:58AM $0.825 $0.105 fallen by 87.27%
$13 New US Patent for Surgical Stroke 22 May 2025 8:20AM $0.790 $0.105 fallen by 86.71%
$13 Investor Presentation 19 May 2025 10:19AM $0.750 $0.105 fallen by 86%
$13 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 8:09AM $0.685 $0.105 fallen by 84.67%
$13 Last Patient Dosed in Phase 2 Stroke Trial 11 Apr 2025 8:21AM $0.670 $0.105 fallen by 84.33%
$13 Notification of cessation of securities - AGN 1 Apr 2025 5:01PM $0.770 $0.105 fallen by 86.36%
$13 Change of Share Registry Details 21 Mar 2025 5:06PM $0.860 $0.105 fallen by 87.79%
$13 Investor Presentation 12 Mar 2025 9:11AM $0.735 $0.105 fallen by 85.71%
$13 Final Director's Interest Notice 3 Mar 2025 8:19AM $0.790 $0.105 fallen by 86.71%
$13 Non-Executive Director Resignation 3 Mar 2025 8:19AM $0.790 $0.105 fallen by 86.71%
$13 Half Yearly Report and Accounts 11 Feb 2025 6:17PM $0.760 $0.105 fallen by 86.18%
$13 Updated - Main TBI Injury Study Annoucement 4 Feb 2025 10:08AM $0.765 $0.105 fallen by 86.27%
$13 ARG-007 Shows Significant Neuroprotection in Main TBI Study 4 Feb 2025 9:23AM $0.700 $0.105 fallen by 85%
$13 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 9:23AM $0.655 $0.105 fallen by 83.97%
$13 Positive DSMB Safety Outcome & Phase 2 Trial Progress Update 30 Jan 2025 9:17AM $0.655 $0.105 fallen by 83.97%
$13 Phase 2 Stroke Clinical Trial Update 10 Dec 2024 9:58AM $0.655 $0.105 fallen by 83.97%
$13 Initial Director's Interest Notice 2 Dec 2024 8:20AM $0.695 $0.105 fallen by 84.89%
$13 Non-Executive Director Appointment 2 Dec 2024 8:20AM $0.695 $0.105 fallen by 84.89%
$13 $2.76m R&D Tax Incentive Cash Rebate Received for FY24 21 Nov 2024 8:17AM $0.700 $0.105 fallen by 85%

51 - 75 of 288 results

Page 3 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.